| Literature DB >> 27569458 |
Toru Hosoi1, Mai Kakimoto2, Keigo Tanaka2, Jun Nomura3, Koichiro Ozawa4.
Abstract
A pharmacological approach to ameliorate Alzheimer's disease (AD) has not yet been established. In the present study, we investigated the pharmacological characteristics of the recently identified memory-enhancing compound, ISRIB for the amelioration of AD. ISRIB potently attenuated amyloid β-induced neuronal cell death at concentrations of 12.5-25 nM, but did not inhibit amyloid β production in the HEK293T cell line expressing the amyloid precursor protein (APP). These results suggest that ISRIB possesses the unique pharmacological property of attenuating amyloid β-induced neuronal cell death without affecting amyloid β production.Entities:
Keywords: Alzheimer's disease; Amyloid β; ISRIB
Mesh:
Substances:
Year: 2016 PMID: 27569458 DOI: 10.1016/j.jphs.2016.08.003
Source DB: PubMed Journal: J Pharmacol Sci ISSN: 1347-8613 Impact factor: 3.337